FDA Authorizes New Long-Acting Monoclonal Antibodies (AZD7442 or EVUSHELD) for Pre-Exposure Prevention of COVID-19 in Certain Individuals

This is the great news we have been waiting for.

CLL Society worked hard to ensure that those “certain individuals” with access to this passive immunity were the most vulnerable, namely the immunocompromised, including those with CLL / SLL.

This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.

Here are the FDA’s official press release and the accompanying FAQ that go into more detail:

• FDA Press release:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure.
• FDA FAQ also live:https://www.fda.gov/media/154703/download.

Here is the press release from AstraZeneca that includes a quote from our own Dr. Brian Koffman:

• Evusheld (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

There is reason to believe the shots could be available very quickly, maybe even later this month. What a Christmas present that would be!

Stay tuned to CLLSociety.org for the latest news. More details to follow. As they say, this is a breaking story and there is much that we don’t yet know.

Stay strong, we are all in this together.

Brian Koffman MDCM (retired) MSEd (he, him, his)
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.